Findings

What do systematic reviews say?

7 questions · 7 findings · 5 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 2 · 28.6%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%

Tranexamic acid vs placebo

All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery

1 finding from 1 review

Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Very low

Summary of findings: Fibrin sealant vs usual care

All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).

1 finding from 1 review

Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and… 2023 · Cochrane Headline outcomes only
RR 0.44 [0.11, 1.76]
3 studies · 585 participants
Very low

IVIg vs prednisolone

Mortality (all‐cause) (up to 30 days) · people undergoing initial treatment for KD

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Metoprolol vs placebo

All‐cause mortality, 30 days1 · patients of any age with AAA less than 30 mm in diameter

Metoprolol showed no clear difference in all‐cause mortality, 30 days1 compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with… 2017 · Cochrane Headline outcomes only
OR 0.17 [0.02, 1.41]
1 study · 227 participants
Low

Subcutaneous unfractionated heparin vs low molecular weight heparin

All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 0.73 [0.5, 1.07]
7 studies · 2272 participants
Low

Hand‐assisted laparoscopic repair vs EVAR

All‐cause mortality/survival (> 30 days) · People undergoing elective abdominal aortic aneurysm repair

The review found no eligible studies for this question.

1 finding from 1 review

Laparoscopic surgery for elective abdominal aortic aneurysm repair 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Subcutaneous unfractionated heparin vs unfractionated heparin

All‐cause mortality (5 days to 12 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (5 days to 12 months) compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 1.74 [0.67, 4.51]
8 studies · 972 participants
Low